289 related articles for article (PubMed ID: 11313385)
1. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
Eo SK; Gierynska M; Kamar AA; Rouse BT
J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
[TBL] [Abstract][Full Text] [Related]
2. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
3. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus.
Lee S; Gierynska M; Eo SK; Kuklin N; Rouse BT
Microbes Infect; 2003 Jun; 5(7):571-8. PubMed ID: 12787733
[TBL] [Abstract][Full Text] [Related]
4. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.
Kuklin N; Daheshia M; Karem K; Manickan E; Rouse BT
J Virol; 1997 Apr; 71(4):3138-45. PubMed ID: 9060677
[TBL] [Abstract][Full Text] [Related]
5. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
6. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
[TBL] [Abstract][Full Text] [Related]
7. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
[TBL] [Abstract][Full Text] [Related]
8. A mucosal vaccination approach for herpes simplex virus type 2.
Tirabassi RS; Ace CI; Levchenko T; Torchilin VP; Selin LK; Nie S; Guberski DL; Yang K
Vaccine; 2011 Jan; 29(5):1090-8. PubMed ID: 21134447
[TBL] [Abstract][Full Text] [Related]
9. Multiple alternating immunizations with DNA vaccine and replication incompetent adenovirus expressing gB of pseudorabies virus protect animals against lethal virus challenge.
Kim SJ; Kim HK; Han YW; Aleyas AG; George JA; Yoon HA; Yoo DJ; Kim K; Eo SK
J Microbiol Biotechnol; 2008 Jul; 18(7):1326-34. PubMed ID: 18667863
[TBL] [Abstract][Full Text] [Related]
10. Flagellin Encoded in Gene-Based Vector Vaccines Is a Route-Dependent Immune Adjuvant.
Rady HF; Dai G; Huang W; Shellito JE; Ramsay AJ
PLoS One; 2016; 11(2):e0148701. PubMed ID: 26844553
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
12. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
13. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands.
Eo SK; Lee S; Kumaraguru U; Rouse BT
Vaccine; 2001 Sep; 19(32):4685-93. PubMed ID: 11535317
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
[TBL] [Abstract][Full Text] [Related]
15. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
16. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
[TBL] [Abstract][Full Text] [Related]
17. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.
Yan Y; Hu K; Fu M; Deng X; Luo S; Tong L; Guan X; He S; Li C; Jin W; Du T; Zheng Z; Zhang M; Liu Y; Hu Q
mSphere; 2021 Apr; 6(2):. PubMed ID: 33910988
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
19. Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.
Ramirez K; Capozzo AV; Lloyd SA; Sztein MB; Nataro JP; Pasetti MF
J Immunol; 2009 Jan; 182(2):1211-22. PubMed ID: 19124765
[TBL] [Abstract][Full Text] [Related]
20. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge.
Li Z; Zhang M; Zhou C; Zhao X; Iijima N; Frankel FR
J Immunol; 2008 Feb; 180(4):2504-13. PubMed ID: 18250460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
